171 related articles for article (PubMed ID: 24871936)
1. Multimeric disintegrin protein polymer fusions that target tumor vasculature.
Janib SM; Gustafson JA; Minea RO; Swenson SD; Liu S; Pastuszka MK; Lock LL; Cui H; Markland FS; Conti PS; Li Z; MacKay JA
Biomacromolecules; 2014 Jul; 15(7):2347-58. PubMed ID: 24871936
[TBL] [Abstract][Full Text] [Related]
2. Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.
Minea R; Helchowski C; Rubino B; Brodmann K; Swenson S; Markland F
Toxicon; 2012 Mar; 59(4):472-86. PubMed ID: 21354198
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
4. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.
Shi P; Aluri S; Lin YA; Shah M; Edman M; Dhandhukia J; Cui H; MacKay JA
J Control Release; 2013 Nov; 171(3):330-8. PubMed ID: 23714121
[TBL] [Abstract][Full Text] [Related]
5. Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo.
Dhandhukia JP; Shi P; Peddi S; Li Z; Aluri S; Ju Y; Brill D; Wang W; Janib SM; Lin YA; Liu S; Cui H; MacKay JA
Bioconjug Chem; 2017 Nov; 28(11):2715-2728. PubMed ID: 28937754
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral Potential of Lansbermin-I, a Novel Disintegrin from Porthidium lansbergii lansbergii Venom on Breast Cancer Cells.
Montealegre-Sánchez L; Gimenes SNC; Lopes DS; Teixeira SC; Solano-Redondo L; de Melo Rodrigues V; Jiménez-Charris E
Curr Top Med Chem; 2019; 19(22):2069-2078. PubMed ID: 31385773
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review.
Schönthal AH; Swenson SD; Chen TC; Markland FS
Biochem Pharmacol; 2020 Nov; 181():114149. PubMed ID: 32663453
[TBL] [Abstract][Full Text] [Related]
8. Bicyclic RGD peptides with high integrin α
Cipriani F; Bernhagen D; García-Arévalo C; de Torre IG; Timmerman P; Rodríguez-Cabello JC
Biomed Mater; 2019 Mar; 14(3):035009. PubMed ID: 30630151
[TBL] [Abstract][Full Text] [Related]
9. Recombinant RGD-disintegrin DisBa-01 blocks integrin α
Danilucci TM; Santos PK; Pachane BC; Pisani GFD; Lino RLB; Casali BC; Altei WF; Selistre-de-Araujo HS
Cell Commun Signal; 2019 Mar; 17(1):27. PubMed ID: 30894182
[TBL] [Abstract][Full Text] [Related]
10. The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.
Sun D; Sun M; Zhu W; Wang Z; Li Y; Ma J
Toxins (Basel); 2015 Feb; 7(2):423-38. PubMed ID: 25658509
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom.
Zhou Q; Hu P; Ritter MR; Swenson SD; Argounova S; Epstein AL; Markland FS
Arch Biochem Biophys; 2000 Mar; 375(2):278-88. PubMed ID: 10700384
[TBL] [Abstract][Full Text] [Related]
12. Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.
Minea RO; Helchowski CM; Zidovetzki SJ; Costa FK; Swenson SD; Markland FS
PLoS One; 2010 Jun; 5(6):e10929. PubMed ID: 20532165
[TBL] [Abstract][Full Text] [Related]
13. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins.
Mahimkar RM; Visaya O; Pollock AS; Lovett DH
Biochem J; 2005 Jan; 385(Pt 2):461-8. PubMed ID: 15361064
[TBL] [Abstract][Full Text] [Related]
14. An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity. Evidence for a functional equivalence of acidic integrin-binding motifs.
Tselepis VH; Green LJ; Humphries MJ
J Biol Chem; 1997 Aug; 272(34):21341-8. PubMed ID: 9261147
[TBL] [Abstract][Full Text] [Related]
15. Berunda Polypeptides: Multi-Headed Fusion Proteins Promote Subcutaneous Administration of Rapamycin to Breast Cancer
Dhandhukia JP; Li Z; Peddi S; Kakan S; Mehta A; Tyrpak D; Despanie J; MacKay JA
Theranostics; 2017; 7(16):3856-3872. PubMed ID: 29109782
[TBL] [Abstract][Full Text] [Related]
16. Disintegrin-like Protein Strategy to Inhibit Aggressive Triple-Negative Breast Cancer.
Limam I; Abdelkarim M; El Ayeb M; Crepin M; Marrakchi N; Di Benedetto M
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569595
[TBL] [Abstract][Full Text] [Related]
17. Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer.
Swenson SD; Silva-Hirschberg C; Markland FS
Methods Mol Biol; 2020; 2068():185-204. PubMed ID: 31576529
[TBL] [Abstract][Full Text] [Related]
18. Design and cellular internalization of genetically engineered polypeptide nanoparticles displaying adenovirus knob domain.
Sun G; Hsueh PY; Janib SM; Hamm-Alvarez S; MacKay JA
J Control Release; 2011 Oct; 155(2):218-26. PubMed ID: 21699930
[TBL] [Abstract][Full Text] [Related]
19. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.
Bridges LC; Tani PH; Hanson KR; Roberts CM; Judkins MB; Bowditch RD
J Biol Chem; 2002 Feb; 277(5):3784-92. PubMed ID: 11724793
[TBL] [Abstract][Full Text] [Related]
20. Self-Assembling VHH-Elastin-Like Peptides for Photodynamic Nanomedicine.
Pille J; van Lith SA; van Hest JC; Leenders WP
Biomacromolecules; 2017 Apr; 18(4):1302-1310. PubMed ID: 28269985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
